6-氯-2-氟-3-甲基苯甲酰氯 | 261762-81-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 6-氯-2-氟-3-甲基苯甲酰氯
• 英文名称: 2-chloro-6-fluoro-3-methylbenzoyl chloride
• CAS: 261762-81-6
• 化学式: C₈H₅Cl₂FO
• mdl: MFCD01631361
• 分子量: 207.032
• InChiKey: XJFKTIHKOKWAEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2916399090
• 包装等级：
  II
• 危险品运输编号：
  UN 3265

反应信息

• 作为反应物：
  描述：

  6-氯-2-氟-3-甲基苯甲酰氯 在 吡啶 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 2-chloro-6-fluoro-3-methyl-N-(2-(4-methylpiperazin-1-yl)-5-nitrophenyl)benzamide
  参考文献：
  名称：

  Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1)

  摘要：

  WD repeat-containing protein 5 (WDR5) is an important component of the multiprotein complex essential for activating mixed-lineage leukemia 1 (MLL1). Rearrangement of the MLL1 gene is associated with onset and progression of acute myeloid and lymphoblastic leukemias, and targeting the WDR5-MLL1 interaction may result in new cancer therapeutics. Our previous work showed that binding of small molecule ligands to WDR5 can modulate its interaction with MLL1, suppressing MLL1 methyltransferase activity. Initial structure activity relationship studies identified N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides as potent and selective antagonists of this protein protein interaction. Guided by crystal structure data and supported by in silico library design, we optimized the scaffold by varying the C-1 benzamide and C-S substituents. This allowed us to develop the first highly potent (K-disp < 100 nM) small molecule antagonists of the WDR5-MLL1 interaction and demonstrate that N-(4-(4-methylpiperazin-1-yl)-3'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide 16d (OICR-9429) is a potent and selective chemical probe suitable to help dissect the biological role of WDR5.

  DOI：

  10.1021/acs.jmedchem.5b01630
• 作为产物：
  描述：

  2-氯-6-氟-3-甲基苯甲酸 在 氯化亚砜 作用下， 以 甲苯 为溶剂， 反应 2.0h， 生成 6-氯-2-氟-3-甲基苯甲酰氯
  参考文献：
  名称：

  Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1)

  摘要：

  WD repeat-containing protein 5 (WDR5) is an important component of the multiprotein complex essential for activating mixed-lineage leukemia 1 (MLL1). Rearrangement of the MLL1 gene is associated with onset and progression of acute myeloid and lymphoblastic leukemias, and targeting the WDR5-MLL1 interaction may result in new cancer therapeutics. Our previous work showed that binding of small molecule ligands to WDR5 can modulate its interaction with MLL1, suppressing MLL1 methyltransferase activity. Initial structure activity relationship studies identified N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides as potent and selective antagonists of this protein protein interaction. Guided by crystal structure data and supported by in silico library design, we optimized the scaffold by varying the C-1 benzamide and C-S substituents. This allowed us to develop the first highly potent (K-disp < 100 nM) small molecule antagonists of the WDR5-MLL1 interaction and demonstrate that N-(4-(4-methylpiperazin-1-yl)-3'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide 16d (OICR-9429) is a potent and selective chemical probe suitable to help dissect the biological role of WDR5.

  DOI：

  10.1021/acs.jmedchem.5b01630

文献信息

• Substituted Spiro-amide Compounds
  申请人：Schunk Stefan

  公开号：US20100249095A1

  公开（公告）日：2010-09-30

  Substituted spiro-amide compounds corresponding to formula I in which R5 through R8, D, X, Y and Z have defined meanings, processes for preparing such spiro-amide compounds, pharmaceutical compositions containing such compounds, and methods of using such spiro-amide compounds for treating and/or inhibiting disorders or disease states mediated at least in part by the bradykinin 1 receptor.

  将与式I相对应的螺环酰胺化合物替代为R5至R8、D、X、Y和Z具有定义含义的过程，用于制备这种螺环酰胺化合物，含有这种化合物的药物组合物，以及使用这种螺环酰胺化合物治疗和/或抑制至少部分由激肽酶1受体介导的疾病或疾病状态的方法。
• [EN] BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS<br/>[FR] PETITES MOLÉCULES CONTENANT DU BORE ET UTILISABLES EN TANT QU'AGENTS ANTIPROTOZOAIRES
  申请人：ANACOR PHARMACEUTICALS INC

  公开号：WO2011019618A1

  公开（公告）日：2011-02-17

  This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. The compounds have the following formula: wherein X is selected from the group consisting of substituted phenyl, substituted or unsubstituted heteroaryl and unsubstituted cycloalkyl; R3a is selected from the group consisting of H1 unsubstituted C1 or C2 or C3 or C4 or C5 or C6 alkyl and unsubstituted C3 or C4 or C5 or C6 cycloalkyl; R3b is selected from the group consisting of H, unsubstituted C1 or C2 or C3 or C4 or C5 or C6 alkyl and unsubstituted C3 or C4 or C5 or C6 cycloalkyl; with the proviso that R3a and R3b, along with the atom to which they are attached, are optionally joined to form a 3 or 4 or 5 or 6 membered ring, with the proviso that R3a and R3b cannot both be H, or a salt thereof.

  这项发明提供了用于治疗原虫感染的新化合物，包含这些化合物的药物组合物，以及这些化合物与至少一种额外治疗有效剂的组合物。这些化合物具有以下结构式：其中X选自取代苯基、取代或未取代杂环芳基和未取代环烷基的组；R3a选自H1未取代的C1或C2或C3或C4或C5或C6烷基和未取代的C3或C4或C5或C6环烷基的组；R3b选自H、未取代的C1或C2或C3或C4或C5或C6烷基和未取代的C3或C4或C5或C6环烷基的组；但R3a和R3b，以及它们连接的原子，可选地结合形成3、4、5或6元环，但R3a和R3b不能同时为H，或其盐。
• Development of a fluorescent chalcone library and its application in the discovery of a mouse embryonic stem cell probe
  作者：Sung-Chan Lee、Nam-Young Kang、Sung-Jin Park、Seong-Wook Yun、Yogeswari Chandran、Young-Tae Chang

  DOI：10.1039/c2cc31662e

  日期：——

  We report the first fluorescent diamino-chalcone library and its application in the discovery of a mouse embryonic stem cell (mESC) probe. CDg4, a novel green fluorescent mESC probe was discovered through a high-content image based screening of 160 members of the chalcone library. Interestingly, the molecular binding target of CDg4 was identified as the glycogen of the stem cell colony surface, rather than a conventional protein target from an intracellular source.

  我们报道了第一个荧光二氨基查尔酮库及其在小鼠胚胎干细胞（mESC）探针发现中的应用。通过对160个查尔酮库成员进行高通量图像筛选，发现了一种新型绿色荧光mESC探针CDg4。有趣的是，CDg4的分子结合靶标被确定为干细胞集落表面的糖原，而不是传统的来自细胞内的蛋白质靶标。
• [EN] METHOD FOR INHIBITING TRYPANSOMA CRUZI<br/>[FR] PROCÉDÉ D'INHIBITION DE TRYPANSOMA CRUZI
  申请人：UNIV HOWARD

  公开号：WO2013016661A1

  公开（公告）日：2013-01-31

  In its broadest aspect, a method for treating a mammalian patient at risk or suffering from a disease caused by a kinetoplastid parasite comprises administering to such subject an effective kinetoplasticidal amount of an imido-substituted 1,4- naphthoquinone to inhibit the kinetoplastid. In an important aspect, a method of inhibiting Trypanosoma cruzi comprises administering to a patient for prophylaxis or to a patient in need of treatment an antitrypanosomal effective amount of an imido-substituted 1 A-naphthoquinone.

  在其最广泛的方面，一种治疗受威胁或患有由原生质体寄生虫引起的疾病的哺乳动物患者的方法包括向该受试者施用有效的威力质体杀灭剂量的亚胺取代的1,4-萘醌以抑制威力体。在一个重要方面，一种抑制克氏锥虫的方法包括向需要预防或治疗的患者施用亚胺取代的1 A-萘醌的抗克氏锥虫有效量。
• [EN] METHODS FOR TREATING LEISHMANIASIS<br/>[FR] MÉTHODES DE TRAITEMENT DE LA LEISHMANIOSE
  申请人：UNIV HOWARD

  公开号：WO2013074930A1

  公开（公告）日：2013-05-23

  Methods are provided to inhibit proliferation of Leishmania parasites, and in particular Leishmania donovani with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an imido-substituted 1,4-naphthoquinone can be used to provide prophylaxis or treatment to a patient in need of treatment against leishmaniasis disease.

  提供了一种方法来抑制利什曼原虫（Leishmania）的增殖，特别是对利什曼东非原虫（Leishmania donovani）使用带有亚胺取代的1,4-萘醌类化合物，包括新颖的化合物。给予亚胺取代的1,4-萘醌类化合物可以用于为需要治疗利什曼病的患者提供预防或治疗。